Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit.
It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.
Read more below.
HTL Biotechnology is proud to support National Biomedicines manufacturing Day, which will take place on June 5, 2025.
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.
We are excited to share that HTL Biotechnology is present at the AMWC 2025 in Monaco.